Yes, Sandostatin Treats Certain Tumors
Sandostatin (octreotide acetate) is FDA-approved for treating specific neuroendocrine tumors, including carcinoid tumors and VIPomas, where it reduces hormone secretion and slows tumor growth.[1] It mimics somatostatin, a natural hormone that inhibits gastrointestinal and pancreatic secretions, helping manage symptoms from hormone-producing tumors.
How Sandostatin Works for Tumors
It binds to somatostatin receptors on tumor cells, suppressing growth factors and hormones like serotonin or vasoactive intestinal peptide (VIP). This provides symptomatic relief in carcinoid syndrome—flushing, diarrhea—and controls tumor progression in acromegaly-related cases, though it's not a cure.[1][2]
Common Tumor Uses and Approvals
- Carcinoid tumors: Reduces severe diarrhea and flushing; approved for patients with malignant carcinoid unresponsive to other therapies.
- VIPomas: Manages profuse watery diarrhea (WDHA syndrome).
- Off-label or investigational: Used in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and sometimes thyroid cancers, based on receptor expression.[2]
Sandostatin LAR (long-acting release) is injected monthly for sustained control.
What Tumors It Doesn't Treat
Not indicated for solid tumors like lung, breast, or colon cancers without neuroendocrine features. It's ineffective against non-hormone-secreting tumors.[1]
Side Effects Patients Report with Tumor Use
Gallstones (up to 50% long-term), abdominal pain, nausea, hyperglycemia, and bradycardia. Tumor patients may experience injection-site reactions or hypothyroidism.[2] Monitor thyroid and gallbladder via ultrasound.
Alternatives for Neuroendocrine Tumors
- Somatuline (lanreotide): Similar somatostatin analog, often interchangeable.
- Signifor (pasireotide): For Cushing's-related tumors.
- Targeted therapies: Everolimus or sunitinib for advanced NETs; PRRT (peptide receptor radionuclide therapy) for somatostatin-receptor positive tumors.[3]
Who Makes Sandostatin and Patent Status
Novartis manufactures it. Key U.S. patents expired around 2010-2018, allowing generics like octreotide acetate injection. Check DrugPatentWatch.com for latest exclusivity details on LAR formulations.[4]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019767s067lbl.pdf
[2] NCCN Guidelines: Neuroendocrine Tumors (2023)
[3] ESMO Guidelines: https://www.esmo.org/guidelines/gastrointestinal-cancers/neuroendocrine-tumours
[4] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/SANDOSTATIN